August 2025

We are proud to share that Laurel Biotherapeutics has been awarded the 2025 Mission BioCapital (MBC) Platinum Ticket. This distinguished recognition provides up to $500,000 in pre-seed funding, access to cutting-edge laboratory facilities, specialized discovery services, and world-class mentorship to accelerate our development of first-in-class therapeutics for cardiorenal disease. Mission BioCapital is a leading accelerator of early-stage biotech companies, pairing capital with support, infrastructure, and a network of experienced operators to help teams move faster. We are excited to build alongside the MBC community as we advance our programs.

August 2025

Proud to join the CDL Advanced Therapies (Fall 2025) cohort. Laurel Biotherapeutics is building AI-enabled and immune-derived antibody therapeutics for cardiorenal dysfunction, targeting cross-talk among cardiovascular, inflammatory, and metabolic pathways, with the goal of reducing patients’ at-home pharmacy burden. Participation in CDL will connect us with seasoned mentors and a strong founder community, helping us sharpen our plan, meet clear development checkpoints, and move our programs closer to patients.

September 2025

LabCentral’s Ignite Golden Tickets support the next generation of powerhouse biotech companies by giving high-potential founders access to resources and networks to advance breakthrough science. This year, five tickets will be awarded to biotech entrepreneurs advancing high-impact innovations for human health, with a focus on emerging founders who have had limited access to industry networks and infrastructure. We’re honored to be a finalist and excited to continue building with the LabCentral community.